ALS drug safety check: new study tests Long-Term effects
NCT ID NCT07571200
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at the long-term safety of an experimental drug called LY4256984 for people with ALS. It enrolls up to 32 participants who have completed a prior ALS trial. The study will follow them for at least 96 weeks to see how well the drug is tolerated over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY4256984
What this could lead to
If successful, this could help confirm that these experimental drugs are safe enough to use in larger trials for ALS.
What could go wrong
This is a very early (Phase 1) study with only 32 people. It focuses on safety, not effectiveness, so it may not lead to a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Universitari de Bellvitge
NOT_YET_RECRUITINGL'Hospitalet de Llobregat, 08907, Spain
Contact
-
Hospital Universitari i Politecnic La Fe
NOT_YET_RECRUITINGValencia, 46026, Spain
Contact
-
McGill University Health Centre
RECRUITINGMontreal, H4A 3J1, Canada
Contact Phone: •••-•••-••••
Contact
-
Sunnybrook Research Institute
NOT_YET_RECRUITINGToronto, M4N 3M5, Canada
Contact
-
UZ Leuven
NOT_YET_RECRUITINGLeuven, 3000, Belgium
Contact Phone: •••-•••-••••
Contact
-
Universitaetsklinikum Ulm
NOT_YET_RECRUITINGUlm, 89081, Germany
Contact Phone: •••-•••-••••
Contact
-
Universitair Medisch Centrum Utrecht
NOT_YET_RECRUITINGUtrecht, 3584 CX, Netherlands
Contact Phone: •••-•••-••••
Contact
-
Universitätsklinikum Schleswig-Holstein
NOT_YET_RECRUITINGLübeck, 23538, Germany
Contact Phone: •••-•••-••••
Contact
-
Universitätsmedizin Rostock
NOT_YET_RECRUITINGRostock, 18147, Germany
Contact Phone: •••-•••-••••
Contact